Abstract
Background:
This study will investigate the effects of Spore Powder of Ganoderma Lucidum (SPGL) on CaSR and apoptosis-related proteins (ARP) in hippocampus tissue of epilepsy following dementia.
Methods:
This study will retrieve all potential studies from both electronic databases (Cochrane Library, EMBASE, MEDLINE, CINAHL, AMED, and CNKI) and other literature sources to assess the effects of SPGL on CaSR and ARP in hippocampus tissue of epilepsy following dementia. We will search all literature sources from the inception to the present. All eligible case-control studies will be included in this study. Two authors will independently carry out literature selection, data collection, and study quality evaluation. Any divergence will be resolved by another author through discussion. RevMan 5.3 software will be employed for data analysis.
Results:
This study will summarize existing evidence to assess the effects of SPGL on CaSR and ARP in hippocampus tissue of epilepsy following dementia.
Conclusions:
The findings of this study may provide helpful evidence of SPGL on CaSR and ARP in hippocampus tissue of epilepsy following dementia.
Systematic review registration:
INPLASY202070041.
Keywords: dementia, epilepsy, spore powder of ganoderma lucidum
1. Introduction
Epilepsy is a very common disorder, affecting about 65 million populations around the world.[1–4] Its incidence is higher in the elderly people, especially for those patients over 65 years old, expect with almost 1 billion patients by 2030.[5–7] It is more common in patients with dementia than general population.[8,9] Although it is reported to be associated with alterations in inhibitory-excitatory systems, its mechanism is still not fully understood.[10–12]
There exists no effective treatment for both epilepsy and dementia. Fortunately, Spore Powder of Ganoderma Lucidum (SPGL) has reported to manage both of them.[13–15] It is reported by exploring CaSR and apoptosis-related proteins (ARP) in hippocampus tissue of rats.[16–32] However, no systematic review has been conducted to address this issue. Thus, this systematic review will investigate the effects of SPGL on CaSR and ARP in hippocampus tissue of rats with epilepsy after dementia.
2. Methods
2.1. Objective
This systematic review aims to evaluate the effects of SPGL on CaSR and ARP in hippocampus tissue of epilepsy following dementia.
2.2. Study registration
This study protocol has registered on INPLASY202070041. It has organized based on the standards of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols Statement.[33]
2.3. Inclusion criteria for study selection
2.3.1. Types of studies
All eligible case-control studies (CCSs) on assessing the effects of SPGL on CaSR and ARP in hippocampus tissue of rats with epilepsy following dementia will be considered for inclusion.
2.3.2. Types of participants
Rats confirmed with epilepsy after dementia will be included in this study.
2.3.3. Types of interventions
In the experimental group, any forms of SPGL were used as the only treatment.
In the control group, no restrictions were applied to the comparator, except SPGL.
2.3.4. Types of outcome measurements
Outcomes include protein and gene expressions of CaSR, c-Fos, Caspase-3, Bcl-2, Bax, Neural Cell Adhesion Molecule 1, proliferating cell nuclear antigen, CyclinD1, livin; and levels of NO, NOS, and interleukin 10 in hippocampus tissue of rats.
2.4. Search methods for study identification
2.4.1. Electronic bibliographic databases
We will search animal studies of question for SPGL on CaSR and ARP in hippocampus tissue of rats with epilepsy following dementia in Cochrane Library, EMBASE, MEDLINE, CINAHL, AMED, and CNKI from inception to the present. We present search strategy with details for Cochrane Library in Table 1. We will adapt similar search strategy to other electronic bibliographic databases.
Table 1.
Search strategy of Cochrane Library Database.
Open in a new tab
2.4.2. Other sources
We will also search other sources to avoid missing potential studies, such as conference proceedings, associated references lists of included studies, and ongoing trials from websites of clinical trial registry.
2.5. Data collection and analysis
2.5.1. Study selection
Two authors will independently perform study selection according to the predefined eligibility criteria. If there are disagreements between both of them, we will invite another author to solve them. There are 2 stages in the process of study selection. At the first stage, we will scan titles/abstracts of all studies to remove duplicates and all irrelevant records. At the second stage, we will read full text of all potential articles to judge whether they can be finally selected in this study. The whole process of study selection will be presented in a flow diagram.
2.5.2. Data extraction and management
Two authors will independently extract data from eligible study in accordance with a predefined standardized data extraction sheet. If we identify any disagreement, we will invite another author to solve it through discussion. We will extract the following information of title, first author, year of publication, species, gender, study methods, details of intervention and control (e.g. time, dosage, and duration), outcome indicators, results, and findings.
2.5.3. Risk of bias assessment
The risk of bias of eligible CCSs will be performed by 2 independent authors using Newcastle-Ottawa Scale.[34] If there is conflict between 2 authors, we will invite another author to clear up such division.
2.5.4. Measurement of treatment effect
Treatment effect of outcome indicators will be estimated using risk ratio and 95% confidence intervals (CIs) for dichotomous data, and mean difference (MD) or standardized MD and 95% CIs for continuous data.
2.5.5. Dealing with missing data
If any unclear or missing data occurs, we will contact primary author to obtain those data by email or phone. If those data is not achievable, we will analyze available data only, and will discuss its potential impacts.
2.5.6. Data synthesis
We will use RevMan 5.3 software to analyze and synthesize outcome data. We will examine heterogeneity across CCSs using Cochrane I2 test. If the value of I2 ≤50% is identified, it means reasonable heterogeneity, and we will place a fixed-effects model. Under such situation, we will carry out meta-analysis if sufficient data is collected with sufficient similarity on the same outcome indicator. If the value of I2 > 50% is found, it indicates substantial heterogeneity, and we will apply a random-effects model. We will identify any possible sources of significant heterogeneity. If meta-analysis is deemed not to be performed, we will report study results by a narrative description.
2.5.7. Reporting bias
We will check reporting bias using Funnel plot and Egger linear regression test to examine funnel plot asymmetry.[35,36]
2.5.8. Subgroup analysis
We will undertake a subgroup analysis based on the different characteristics of subjects, treatment schedules, and outcome variables.
2.5.9. Sensitivity analysis
We will carry out a sensitivity analysis to check the stability and robustness of study results according to the methodological quality, sample size, and missing data.
2.5.10. Dissemination and ethics
We expect to publish this study through a peer-reviewed journal. This study does not need ethic approval, because we will only collect data from eligible studies.
3. Discussion
Although a variety of studies have reported the effects of SPGL on epilepsy and dementia,[13–32] no systematic review investigated the effects of SPGL on CaSR and ARP in hippocampus tissue of rats with epilepsy after dementia. This systematic review will first summarize current available literature to assess the effects of SPGL on CaSR and ARP in hippocampus tissue of rats with epilepsy following dementia. We will include all potential eligible studies. The findings of this study will provide evidence to help judge whether SPGL is effective on CaSR and ARP in hippocampus tissue of rats with epilepsy after dementia.
Author contributions
Conceptualization: Li-hong Qin, Chen Wang, Yao Feng, Shu-ping Zhang.
Data curation: Li-hong Qin, Xiao-xue Jiang, You Song.
Formal analysis: Xiao-xue Jiang, Yao Feng, Li-wei Qin.
Funding acquisition: Shu-ping Zhang.
Investigation: Shu-ping Zhang.
Methodology: Li-hong Qin, Chen Wang, Xiao-xue Jiang, You Song, Li-wei Qin.
Project administration: Shu-ping Zhang.
Resources: Li-hong Qin, Chen Wang, Xiao-xue Jiang, You Song, Yao Feng, Li-wei Qin.
Software: Li-hong Qin, Chen Wang, Xiao-xue Jiang, You Song, Yao Feng, Li-wei Qin.
Supervision: Shu-ping Zhang.
Validation: Li-hong Qin, Chen Wang, Xiao-xue Jiang, You Song, Li-wei Qin, Shu-ping Zhang.
Visualization: Li-hong Qin, Yao Feng, Li-wei Qin, Shu-ping Zhang.
Writing – original draft: Li-hong Qin, Chen Wang, Xiao-xue Jiang, You Song, Yao Feng, Shu-ping Zhang.
Writing – review & editing: Li-hong Qin, Chen Wang, Yao Feng, Li-wei Qin, Shu-ping Zhang.
Footnotes
Abbreviations: ARP = apoptosis-related proteins, CIs = confidence intervals, MD = mean difference, SPGL = Spore Powder of Ganoderma Lucidum.
How to cite this article: Qin Lh, Wang C, Jiang Xx, Song Y, Feng Y, Qin Lw, Zhang Sp. Effects of spore powder of ganoderma lucidum on CaSR and apoptosis-related proteins in hippocampus tissue of epilepsy following dementia: a protocol of systematic review. Medicine. 2020;99:33(e21711).
L-hQ and CW contributed equally to this study.
This work was supported by the Heilongjiang Natural Science Foundation (C201242); Heilongjiang Provincial Colleges and Universities Basic Research Business Fee Project (2019-KYYWF-1350). In this study, the funder just provided the financial support for this work, and did not involve in any parts of this study, such as design, writing, and publication.
The authors have no conflicts of interest to disclose.
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
References
- [1].Sen A, Jette N, Husain M, et al. Epilepsy in older people. Lancet2020;395:735–48. [DOI] [PubMed] [Google Scholar]
- [2].Beghi E.The epidemiology of epilepsy. Neuroepidemiology2020;54:185–91. [DOI] [PubMed] [Google Scholar]
- [3].Birbeck GL.Epilepsy care in developing countries: part I of II. Epilepsy Curr2010;10:75–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].Lezaic N, Roussy J, Masson H, et al. Epilepsy in the elderly: unique challenges in an increasingly prevalent population. Epilepsy Behav2020;102:106724. [DOI] [PubMed] [Google Scholar]
- [5].Kotloski RJ, Dowding J, Hermann BP, et al. Epilepsy and aging. Handb Clin Neurol2019;167:455–75. [DOI] [PubMed] [Google Scholar]
- [6].Beghi E, Giussani G.Aging and the epidemiology of epilepsy. Neuroepidemiology2018;51:216–23. [DOI] [PubMed] [Google Scholar]
- [7].Sen A, Capelli V, Husain M.Cognition and dementia in older patients with epilepsy. Brain2018;141:1592–608. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Forsgren L, Edvinsson SO, Blomquist HK, et al. Epilepsy in a population of mentally retarded children and adults. Epilepsy Res1990;6:234–48. [DOI] [PubMed] [Google Scholar]
- [9].Hesdorffer DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology1996;46:727–30. [DOI] [PubMed] [Google Scholar]
- [10].Iwata A.Confluence of dementia and epilepsy pathologies. Brain Nerve2014;66:1379–84. [DOI] [PubMed] [Google Scholar]
- [11].Ishigaki S, Sugimoto A, Kawamura M.Epilepsy and dementia. Nihon Rinsho2014;72:926–30. [PubMed] [Google Scholar]
- [12].Sugimoto A, Futamura A, Kawamura M.Epilepsy and dementia. Brain Nerve2012;64:1399–404. [PubMed] [Google Scholar]
- [13].Qin LH, Wang C, Qin LW, et al. Spore powder of Ganoderma lucidum for Alzheimer's disease: a protocol for systematic review. Medicine (Baltimore)2019;98:e14382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Wang GH, Wang LH, Wang C, et al. Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease: a pilot study. Medicine (Baltimore)2018;97:e0636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [15].Wang GH, Li X, Cao WH, et al. A retrospective study of ganoderma lucidum spore powder for patients with epilepsy. Medicine (Baltimore)2018;97:e10941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Liu H.Effect of Ganoderma lucidum spore powder on brain tissue BDNF and livin of epilepsy rats. Chin Med Guide2017;15:22–3. [Google Scholar]
- [17].Liu H.Effect of Ganoderma lucidum spore powder on mitochondrial calcium and c-Fos in brain tissue of epilepsy rats. Chin Med Guide2017;15:51–2. [Google Scholar]
- [18].Zhang JB, Song HJ, Liu S, et al. Studies on the expression of caspase-9 activated by pentylenetetrazole in ganoderma lucidum spore powder. Adv Mod Biomed2016;16:1850–3. [Google Scholar]
- [19].Zhang JB, Wang SQ, Zhang YP, et al. Studies on the expression of bad, bcl-xl and p53 activated by pentylenetetrazol in lucid ganoderma spore powder. Chin J Eugen Gen2015;23:24–7. [Google Scholar]
- [20].Zhang JB, Wang SQ, Zhang SH, et al. Studies on Ganoderma lucidum spore powder on the expression of bax activated by pentylenetetrazole in hippocampal nerve cells. Chin J Eugen Gen2012;20:27–8. [Google Scholar]
- [21].Li J, Yu HB, Yu HT, et al. Effects of Ganoderma lucidum spore powder on Caspase-3, NO, NOS in pentylenetetrazol-induced epilepsy rats. Chin Patent Med2012;34:2007–8. [Google Scholar]
- [22].Zhang JB, Wang SQ, Zhang H, et al. Studies on Ganoderma lucidum spore powder on the expression of bcl-2 activated by pentylenetetrazole in hippocampal nerve cells. Heilongjiang Med Sci2012;35:34–5. [Google Scholar]
- [23].Wang SQ, Zhang JH, Wang SX, et al. Changes of brain tissue HO-1, cAMP, cGMP and serum NSE in rats with pentylenetetrazol (PTZ)-induced epilepsy and Ganoderma spores Powder intervention. ShiZhen Guo Yi Guo Yao2012;23:791–3. [Google Scholar]
- [24].Wang SQ, Di WH, Ma XR, et al. Changes of NO and NOS in brain tissue of PTZ-induced epilepsy rats and intervention of Ganoderma spore powder. Heilongjiang Med Sci2011;34:79–80. [Google Scholar]
- [25].Wang WQ, Zhang ML, Yu HB, et al. Effects of Ganoderma lucidum spore powder on NO and NOS in brain tissue of pentylenetetrazol-induced epilepsy rats. Chin J Geronto2011;31:2004–5. [Google Scholar]
- [26].Zhang H, Du XN, Zhu JL, et al. Effects of Ganoderma lucidum spore powder on the expression of NCAM-L1 in the hippocampus of epilepsy rats. Heilongjiang Med Sci2011;34:35. [Google Scholar]
- [27].Li J, Yu HB, Wang SQ, et al. Effects of Ganoderma lucidum spore powder on Livin and Ca(2+) in epileptic rats. Heilongjiang Med Sci2010;33:105. [Google Scholar]
- [28].Du X, Wang S, Zhang H.The effect of Ganoderma lucidum spore powder on the expression of NCAM-1 in the hippocampus of epilepsy rats. Heilongjiang Med Sci2009;32:6. [Google Scholar]
- [29].Jiamusi University, Du XN.Studies on the Effects of Ganoderma Lucidum Spore Powder on NCAM-1 and NCAM-L1 in the Hippocampus of PTZ-Induced Epileptic Rats. 2009;(Dissertation). [Google Scholar]
- [30].Jiamusi University, Lv YT.Effects of Ganoderma lucidum spore powder on changes of PCNA and CyclinD1 in cerebral cortex and hippocampus of pentylenetetrazol-induced epilepsy rats. 2009;(Dissertation). [Google Scholar]
- [31].Li J, Yu HB, Kang YM, et al. Effects of Ganoderma lucidum spore powder on learning and memory, caspase-3 and livin in epileptic rats. Chin J Pathophy2009;25:386–8. [Google Scholar]
- [32].Wang WQ, Wang SQ, Liu YX, et al. Effects of Ganoderma lucidum spore powder on IL-1β and c-Fos in brain tissue of epilepsy rats. Chin J Pathophy2007;6:1149–52. [Google Scholar]
- [33].Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev2015;4:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [34].Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med2015;8:2–10. [DOI] [PubMed] [Google Scholar]
- [35].Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ2000;320:1574–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [36].Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
